This is a routine annual meeting filing with no material financial or operational news. Monitor upcoming quarterly results for pipeline updates on CASGEVY and other gene-editing programs, which are the primary catalysts for CRSP.
Price Chart
Executive Summary
CRISPR Therapeutics held its 2026 Annual General Meeting on June 4, 2026, where shareholders approved routine items including the re-election of all 11 board members, the 2026 Stock Option and Incentive Plan, amendments to the articles of association, and increases to the capital band and conditional share capital. No financial results, guidance, or material operational updates were disclosed — this is a standard governance filing with no immediate trading catalyst.
Key Facts
- Shareholders approved the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan, replacing the 2018 Plan.
- All 11 incumbent directors were re-elected, including CEO Samarth Kulkarni as chairman.
- Shareholders approved an increase to the company's capital band and conditional share capital for convertible instruments.
- Amended articles of association were approved and become effective upon Swiss commercial register registration on or about June 5, 2026.
- Ernst & Young AG and Ernst & Young LLP were re-elected as statutory auditor and independent registered public accounting firm, respectively.
- No financial results, revenue figures, earnings, or guidance were reported in this filing.
Financial Impact
No financial impact — routine governance and compensation plan renewal.
Risk Factors
- No immediate risks identified from this filing.
- Equity dilution risk from the new 2026 Stock Option and Incentive Plan is standard and not material at this stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-257593 |
| Document: crsp-20260604.htm | 0001193125-26-257593 |
| Document: crsp-ex10_1.htm | 0001193125-26-257593 |
| Document: crsp-ex10_2.htm | 0001193125-26-257593 |
| Document: crsp-ex10_3.htm | 0001193125-26-257593 |
| Document: crsp-ex10_4.htm | 0001193125-26-257593 |
| Document: crsp-ex10_5.htm | 0001193125-26-257593 |
| Document: crsp-ex10_6.htm | 0001193125-26-257593 |
| Document: crsp-ex10_7.htm | 0001193125-26-257593 |
| Document: 0001193125-26-257593-index-headers.html | 0001193125-26-257593 |
| Document: 0001193125-26-257593-index.html | 0001193125-26-257593 |
| Document: 0001193125-26-257593.txt | 0001193125-26-257593 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Insider Cluster | $50.50 | awaiting T+20 | — | $49.01 (+2.95%) |
Oct 19, 2026 7d ago | 8-K | $49.88 | awaiting T+20 | — | $49.01 (−1.74%) |
Oct 16, 2026 10d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.01 (−2.06%) |
Oct 16, 2026 10d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.01 (+2.06%) |
Oct 15, 2026 11d ago | Insider Cluster | $49.25 | awaiting T+20 | — | $49.01 (−0.49%) |
Oct 14, 2026 12d ago | 144 | $51.52 | awaiting T+20 | — | $49.01 (−4.87%) |
Oct 6, 2026 20d ago | 144 | $52.35 | awaiting T+20 | — | $49.01 (−6.38%) |
Sep 24, 2026 4w ago | Insider Cluster | $54.23 $49.39 | ▲ +8.92% | ▲ +7.45% | $49.01 (+9.63%) |
Aug 28, 2026 8w ago | Press Release | $57.72 $54.23 | ▼ −6.05% | ▼ −6.56% | $49.01 (−15.09%) |
Aug 3, 2026 12w ago | Press Release | $53.07 $56.82 | ▲ +7.07% | ▲ +8.30% | $49.01 (−7.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers